Literature DB >> 26004056

Virtually-induced threat in Parkinson's: Dopaminergic interactions between anxiety and sensory-perceptual processing while walking.

Kaylena A Ehgoetz Martens1, Colin G Ellard2, Quincy J Almeida3.   

Abstract

Research evidence has suggested that anxiety influences gait in PD, with an identified dopa-sensitive gait response in highly anxious PD. It has been well-established that accurate perception of the environment and sensory feedback is essential for gait. Arguably since sensory and perceptual deficits have been noted in PD, anxiety has the potential to exacerbate movement impairments, since one might expect that reducing resources needed to overcome or compensate for sensory-perceptual deficits may lead to even more severe gait impairments. It is possible that anxiety in threatening situations might consume more processing resources, limiting the ability to process information about the environment or one's own movement (sensory feedback) especially in highly anxious PD. Therefore, the current study aimed to (i) evaluate whether processing of threat-related aspects of the environment was influenced by anxiety, (ii) evaluate whether anxiety influences the ability to utilize sensory feedback in PD while walking in threatening situations, and (iii) further understand the role of dopaminergic medication on these processes in threatening situations in PD. Forty-eight participants (24 HC; 12 Low Anxious [LA-PD], 12 Highly Anxious [HA-PD]) completed 20 walking trials in virtual reality across a plank that was (i) located on the ground (GROUND) (ii) located above a deep pit (ELEVATED); while provided with or without visual feedback about their lower limbs (+VF; -VF). After walking across the plank, participants were asked to judge the width of the plank they had just walked across. The plank varied in size from 60-100 cm. Both ON and OFF dopaminergic medication states were evaluated in PD. Gait parameters, judgment error and self-reported anxiety levels were measured. Results showed that HA-PD reported greater levels of anxiety overall (p<0.001) compared to HC and LA-PD, and all participants reported greater anxiety during the ELEVATED condition compared to GROUND (p=0.01). PD had similar judgment error as HC. Additionally, medication state did not significantly influence judgment error in PD. More importantly, HA-PD were the only group that did not adjust their step width when feedback was provided during the GROUND condition. However, medication facilitated a reduction in ST-CV when visual feedback was available only in the HA-PD group. Therefore, the current study provides evidence that anxiety may interfere with information processing, especially utilizing sensory feedback while walking. Dopaminergic medication appears to improve utilization of sensory feedback in stressful situations by reducing anxiety and/or improving resource allocation especially in those with PD who are highly anxious.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety; Dopaminergic replacement therapy; Parkinson's disease; Perception; Sensory feedback; Virtual reality

Mesh:

Substances:

Year:  2015        PMID: 26004056     DOI: 10.1016/j.neuropsychologia.2015.05.015

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  10 in total

1.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

2.  Motion and emotion: anxiety-axial connections in Parkinson's disease.

Authors:  Rastislav Šumec; Irena Rektorová; Robert Jech; Kateřina Menšíková; Jan Roth; Evžen Růžička; Dana Sochorová; Ladislav Dušek; Petr Kaňovský; Ivan Rektor; Tomáš Pavlík; Pavel Filip; Martin Bareš
Journal:  J Neural Transm (Vienna)       Date:  2016-11-23       Impact factor: 3.575

Review 3.  Decision making in Parkinson's disease: An analysis of the studies using the Iowa Gambling Task.

Authors:  Laura Colautti; Paola Iannello; Maria Caterina Silveri; Alessandro Antonietti
Journal:  Eur J Neurosci       Date:  2021-11-09       Impact factor: 3.698

4.  Compensatory Postural Adjustments in an Oculus Virtual Reality Environment and the Risk of Falling in Alzheimer's Disease.

Authors:  Miguel F Gago; Darya Yelshyna; Estela Bicho; Hélder David Silva; Luís Rocha; Maria Lurdes Rodrigues; Nuno Sousa
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-06-25

5.  Walking in fully immersive virtual environments: an evaluation of potential adverse effects in older adults and individuals with Parkinson's disease.

Authors:  Aram Kim; Nora Darakjian; James M Finley
Journal:  J Neuroeng Rehabil       Date:  2017-02-21       Impact factor: 4.262

6.  Investigating Therapies for Freezing of Gait Targeting the Cognitive, Limbic, and Sensorimotor Domains.

Authors:  Rebecca Chow; Bryan P Tripp; Daniel Rzondzinski; Quincy J Almeida
Journal:  Neurorehabil Neural Repair       Date:  2021-02-09       Impact factor: 3.919

Review 7.  Sensory Attenuation in Sport and Rehabilitation: Perspective from Research in Parkinson's Disease.

Authors:  Joshua Kearney; John-Stuart Brittain
Journal:  Brain Sci       Date:  2021-04-30

8.  Freezing of Gait in Parkinson's Disease: An Overload Problem?

Authors:  Eric N Beck; Kaylena A Ehgoetz Martens; Quincy J Almeida
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

9.  The effects of anxiety and external attentional focus on postural control in patients with Parkinson's disease.

Authors:  Seyede Zohreh Jazaeri; Akram Azad; Hajar Mehdizadeh; Seyed Amirhassan Habibi; Mahbubeh Mandehgary Najafabadi; Zakieh Sadat Saberi; Hawre Rahimzadegan; Saeed Moradi; Saeed Behzadipour; Mohamad Parnianpour; Ghorban Taghizadeh; Kinda Khalaf
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

10.  Sensory focused exercise improves anxiety in Parkinson's disease: A randomized controlled trial.

Authors:  Eric N Beck; Mary T Y Wang; Brittany N Intzandt; Quincy J Almeida; Kaylena A Ehgoetz Martens
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.